The key translational question is whether HF’s broader mechanism, trading single-target potency for multi-pathway activity, can achieve therapeutic windows superior to or complementary with established MDM2 inhibitors, a hypothesis testable only through rigorous head-to-head preclinical comparisons and eventual clinical trials. Here, MDM2 is linked to hydrops fetalis.